Olivier Brandicourt, MD; Rush D. Holt, PhD; and Mary L. (Nora) Disis, MD, are highlighted.

Olivier Brandicourt, MD, began his role as CEO of the international drugmaker Sanofi on April 2. A 28-year veteran of the pharmaceutical industry, Brandicourt most recently served as chairman of the Board of Management of Bayer HealthCare AG. Prior to that, he held numerous positions of increasing responsibility within other global pharmaceutical companies, including Parke-Davis/Warner-Lambert and Pfizer, where he was a member of the executive leadership team from 2010–2013. After completing his medical degree, he practiced medicine for 2 years in the Congo and then spent several years researching malaria.

Rush D. Holt, PhD, became CEO of the American Association for the Advancement of Science and executive publisher of the Science family of journals in February, succeeding Alan I. Leshner, who had held the position for 13 years. Previously, Holt represented New Jersey's 12th District in the U.S. House of Representatives from 1999 until this past January. In addition, he has taught physics and public policy courses, worked as an arms control expert at the U.S. State Department, and served as assistant director of the Plasma Physics Laboratory at Princeton University.

Mary L. (Nora) Disis, MD, became the editor-in-chief of the new journal JAMA Oncology, which was launched in February. A professor of medicine and associate dean of translational science at the University of Washington, Seattle, and a member of the Fred Hutchinson Cancer Research Center, Disis specializes in breast and ovarian cancer immunology and immunotherapy. She is one of a group of researchers who discovered that HER-2/neu is a tumor antigen. She and her research team are developing vaccines and other therapies that target specific antigens.

For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.